Two-domain vascular disruptive agents in cancer therapy

Current Cancer Drug Targets

Volumn 4, Issue 6, 2004, Pages 501-509

  Szala, Stanislaw ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

Cancer therapy.; Tumor vessels; Vascular disruptive agents

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; COMBRETASTATIN; CYTOSTATIC AGENT; DIPHTHERIA TOXIN; DOXORUBICIN; IMMUNOTOXIN; PEPTIDE DERIVATIVE; PSEUDOMONAS EXOTOXIN; TES 23 ANTIBODY; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1 ANTIBODY; VASCULOTROPIN 121; VASCULOTROPIN 165 ANTIBODY; VASCULOTROPIN ANTIBODY;

ANGIOGENESIS; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG CONJUGATION; DRUG METABOLISM; DRUG SYNTHESIS; HUMAN; NONHUMAN; PHARMACODYNAMICS; PROTEIN DOMAIN; REVIEW; SIDE EFFECT; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 4644236945     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009043332826     Document Type: Review

References (51)

1. Folkman, J. What is the Evidence that Tumours are Angiogenesis Dependent? J. Natl. Cancer. Inst. 1990, 82, 4-6.
2. Folkman, J. New Perspectives in Clinical Oncology from Angiogenesis Research. Eur. J. Cancer 1996, 32A, 2534-2539.
3. Kerbel, R.; Folkman, J. Clinical Translation of Angiogenesis Inhibitors. Nature Rev. Cancer 2002, 2, 727-739.
4. Denekamp, J. Vascular Endothelium as the Vulnerable Element in Tumors. Acta Radiol. Oncol. 1984, 23, 217-225.
5. Denekamp, J. Angiogenesis, Neovascular Proliferation and Vascular Pathophysiology as Targets for Cancer Therapy. Brit. J. Radiol. 1993, 66, 181-196.
6. Scappaticci, F. A. Mechanisms and Future Directions for Angiogenesis-Based Cancer Therapies. J. Clin. Oncol. 2002, 20, 3906-3927.
7. Verheul, H. M. W.; Voest, E. E.; Schlingemann, R. O. Are Tumours Angiogenesis-Dependent? J. Pathol. 2004, 202, 5-13.
8. Kerbel, R. S. Tumor Angiogenesis: Past, Present and the New Future. Carcinogenesis 2000, 21, 505-515.
9. Kerbel, R. S. Clinical Trials of Antiangiogenic Drugs: Opportunities, Problems, and Assessment of Initial Results. J. Clin. Oncol. 2001, 19, 45s-49s.
10. Siemann, D. W.; Chaplin, D. J.; Horsman M. R. Vascular-Targeting Therapies for Treatment of Malignant Disease. Cancer 2004, 100, 2491-2499.
11. Schraa, A. J.; Everts, M.; Kok, R. J.; Ásgeirsdóttir, S. A.; Meijer, D. K. F.; de Leij, L. F. M. H.; Molema, G. Development of Vasculature Targeting for the Treatment of Cancer and Chronic Inflammatory Diseases. Biotechnol. Ann. Rev. 2002, 8, 133-166.
12. Allen, T. M. Ligand-Targeted Therapeutics in Anticancer Therapy. Nature Rev. Cancer 2002, 2, 750-763.
13. Thorpe, P. E. Vascular Targeting Agents as Cancer Therapeutics. Clin. Cancer Res. 2004, 10, 415-427.
14. Thorpe, P. E.; Ran, S. Tumor Infraction by Targeting Tissue Factor to Tumor Vasculature. Cancer J. 2000, 6, S237-S244.
15. Brekken, R. A.; Li, C.; Kumar, S. Strategies for Vascular Targeting in Tumors. Int J. Cancer 2002, 100, 123-130.
16. Thorpe, P. E.; Chaplin, D. J.; Blakey, D. C. The First International Conference on Vascular Targeting: Meeting Overview. Cancer Res. 2003, 63, 1144-1147.
17. Tozer, G. M.; Kanthou, C.; Parkins, C.; Hill, S. A. The Biology of the Combretastatins as Tumour Vascular Targeting Agents. Int. J. Exp. Pathol. 2002, 83, 21-38.
18. Baguley, B. C. Antivascular Therapy of Cancer: DMXAA. Lancet Oncol. 2003, 4, 141-148.
19. Payne, G. Progress in Immunoconjugate Cancer Therapeutics. Cancer Cell 2003, 3, 207-212.
20. Yancopoulos, G. D.; Davis, S.; Gale, N. W.; Rudge, J. S.; Wiegand, S. J.; Holash, J. Vascular-Specific Growth Factors and Blood Vessel Formation. Nature 2000, 407, 242-248.
21. Longo, R.; Sarmiento, R.; Fanelli, M.; Capaccetti, B.; Gattuso, D.; Gasparini, G. Anti-Angiogenic Therapy: Rationale, Challenges and Clinical Studies. Angiogenesis 2002, 5, 237-256.
22. Tonini, T.; Rossi, F.; Claudio, P. P. Molecular Basis of Angiogenesis and Cancer. Oncogens 2003, 22, 6549-6556.
23. Arora, N.; Masood, R.; Zheng, T.; Cai, J.; Smith, D. L.; Gill, P. S. Vascular Endothelial Growth Factor Chimeric Toxin is Highly Active Against Endothelial Cells. Cancer Res. 1999, 59, 183-188.
24. Wild, R.; Dhanabal, M.; Olson, T. A.; Ramakrishnan, S. Inhibition of Angiogenesis and Tumour Growth by VEGF121-Toxin Conjugate: Differential Effect on Proliferating Cells. Brit. J. Cancer 2000, 83, 1077-1083.
25. 121/rGelonin Chimeric Fusion Toxin Targeting the Neovasculature of Solid Tumors. Proc. Natl. Acad. Sci. USA 2002, 99, 7866-7871.
26. Arap, W.; Pasqualini, R.; Ruoslahti, E. Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model. Science 1999, 279, 377-380.
27. Ellerby, H. M.; Arap, W.; Ellerby, L. M.; Kain, R.; Andrusiak, R.; Del Rio, G.; Krajewski, S.; Lombardo, C. R.; Rao, R.; Ruoslahti, E.; Bredesen, D. E.; Pasqualini, R. Anti-Cancer Activity of Targeted Pro-Apoptotic Peptides. Nature Med. 1999, 5, 1032-1038.
28. Erbacher, P.; Remy, J. -S.; Behr, J. -P. Gene Transfer with Synthetic Virus-Like Particles Via the Integrin-Mediated Endocytosis Pathway. Gene Ther. 1999, 6, 138-145.
29. Hood, J. D.; Bednarski, M.; Frausto, R.; Guccione, S.; Reisfeld, R. A.; Xiang, R.; Cheresh, D. A. Tumor Regression by Targeted Gene Delivery to the Neovasculature. Science 2002, 296, 2404-2407.
30. Hood, J. D.; Cheresh, D. A. Role of Integrins in Cell Invasion and Migration. Nature Rev. Cancer 2002, 2, 91-100.
31. Isberg, R. R. Discrimination Between Intracellular Uptake and Surface Adhesion of Bacterial Pathogens. Science 1991, 252, 934-938.
32. Ran, S.; Gao, B.; Duffy, S.; Watkins, L.; Rote, N.; Thorpe, P. E. Infarction of Solid Hodgkin's Tumors in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature. Cancer Res. 1998, 58, 4646-4653.
33. Halin, C.; Rondini, S.; Nilsson, F.; Berndt, A.; Kosmehl, H.; Zardi, L.; Neri, D. Enhancement of the Antitumor Activity of Interleukin-12 by Targeted Delivery to Neovasculature. Nature Biotech. 2002, 20, 264-269.
34. Portielje, J. E. A.; Gratama, J. W.; van Ojik, H. H.; Stoter, G.; Kruit, W. H. J. IL-12: a Promising Adjuvant for Cancer Vaccination. Cancer Immunol. Immunother. 2003, 52, 133-144.
35. Carnemolla, B.; Borsi, L.; Balza, E.; Castellani, P.; Meazza, R.; Berndt, A.; Ferrini, S.; Kosmehl, H.; Neri, D.; Zardi, L. Enhancement of Antitumor Properties of Interleukin-2 by in Targeted Delivery to the Tumor Blood Vessel Extracellular Matrix. Blood 2002, 99, 1659-1665.
36. Halin, C.; Gafner, V.; Villani, M. E.; Borsi, L.; Berndt, A.; Kosmehl, H.; Zardi, L.; Neri, D. Synergistic Therapeutic Effect of Tumor Targeting Antibody Fragment, Fused to Interleukin 12 and to Tumor Necrosis Factor α. Cancer Res. 2003, 63, 3203-3210.
37. van Hagen, P. M.; Breeman, W. A. P.; Bernard, H. F.; Schaar, M.; Mooij, C. M.; Srinivasan, A.; Schmidt, M. A.; Krenning, E. P.; de Jong, M. Evaluation of a Radiolabelled Cyclic DTPA-RGD Analogue for Tumor Imaging and Radionuclide Therapy. Int. J. Cancer 2000, 90, 186-198.
38. Goldenberg, D. M. Advancing Role of Radiolabeled Antibodies in the Therapy of Cancer. Cancer Immunol. Immunother. 2003, 52, 281-296.
39. Tsunoda, S.; Ohizumi, I.; Matsui, J.; Koizumi, K.; Wakai, Y.; Makimoto, H.; Tsutsumi, Y.; Utoguchi, N.; Taniguchi, K.; Saito, H.; Harada, N.; Ohsugi, Y.; Mayumi, T. Specific Binding of TES-23 Antibody to Tumour Vascular Endothelium in Mice, Rats and Human Cancer Tissue: a Novel Drug Carrier for Cancer Targeting Therapy. Brit. J. Cancer 1999, 81, 1155-1161.
40. Ramakrishnan, S.; Olson, T. A.; Bauten, V. L.; Mohanraj, D. Vascular Endothelial Growth Factor-Toxin Conjugate Specifically Inhibits KDR/flk-1-Positive Endothelial Cell Proliferation In Vitro and Angiogenesis In Vivo. Cancer Res. 1996, 56, 1324-1330.
41. Burrows, F. J.; Thorpe, P. E. Eradication of Large Solid Tumors in Mice with an Immunotoxin Directed Against Tumor Vasculature. Proc. Natl. Acad. Sci. USA 1993, 90, 8996-9000.
42. Matsuno, F.; Haruta, Y.; Kondo, M.; Tsai, H.; Barcos, M.; Seon, B. K. Induction of Lasting Complete Regression of Preformed Distinct Solid Tumors by Targeting the Tumor Vasculature Using Two New Anti-Endoglin Monoclonal Antibodies. Clin. Cancer Res. 1999, 5, 371-382.
43. Huang, X.; Molena, G.; King, S.; Watkins, L.; Edgington, T. S.; Thorpe, P. E. Tumor Infraction in Mice by Antibody-Directed Targeting of Tissue Factor to Tumor Vasculature. Science 1997, 275, 547-550.
44. Nilsson, F.; Kosmehl, H.; Zardi, L.; Neri, D. Targeted Delivery of Tissue Factor to the ED-B Domain of Fibronectin, a Marker of Angiogenesis, Mediates the Infarction of Solid Tumors in Mice. Cancer Res. 2001, 61, 711-716.
45. Liu, C.; Huang, H.; Doñate, F.; Dickinson, C.; Santucci, R.; El-Sheikh, A.; Vessella, R.; Edgington, T. Prostate-Specific Membrane Antigen Directed Selective Thrombotic Infarction of Tumors. Cancer Res. 2002, 62, 5470-5475.
46. Backer, M. V.; Aloise, R.; Przekop, K.; Stoletov, K.; Backer, J. M. Molecular Vehicles for Targeted Drug Delivery. Bioconjugate Chem. 2002, 13, 462-467.
47. Hendrix, M. J. C.; Seftor, E. A.; Hess, A. R.; Seftor, R. E. B. Vasculogenic Mimicry and Tumour-Cell Plasticity: Lessons from Melanoma. Nature Rev. Cancer 2003, 3, 411-421.
48. Marty, C.; Odermatt, B.; Schott, H.; Neri, D.; Ballmer-Hofer, K.; Klemenz, R.; Schwendener, R. A. Cytotoxic Targeting of F9 Teratocarcinoma Tumours with Anti-ED-B Fibronectin scFv Antibody Modified Liposomes. Brit. J. Cancer 2002, 87, 106-112.
49. Millar, A. W.; Lynch, K. P. Rethinking Clinical Trials for Cytostatic Drugs. Nature Rev. Cancer 2003, 3, 540-545.
50. Schlick, J. -L.; Dulieu, P.; Desvoyes, B.; Adami, P.; Radom, J.; Jouvenot, M. Cytotoxic Activity of a Recombinant GnRH-PAP Fusion Toxin on Human Tumor Cell Lines. FEBS Lett. 2000, 472, 241-246.
51. Sivridis, E.; Giatromanolaki, A.; Koukourakis, M. I. The Vascular Network of Tumours - What is it not for? J. Pathol. 2003, 201, 173-180.